Cytokinetics ALS Drug Fails

Cytokinetics, a biotechnology company, had hoped that by focusing on improving the function of muscle, not nerves, it could have an impact on lung function in patients with amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease, a nerve-destroying disorder. It didn't work.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Adding rasagiline to riluzole did not extend survival, the primary endpoint, in amyotrophic lateral sclerosis, but post hoc analysis suggests it may benefit those deemed'fast progressors. 'Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: Available online 20 June 2018 Source:Molecular Immunology Author(s): Anne-Lene Kjældgaard, Katrine Pilely, Karsten Skovgaard Olsen, Stephen Wørlich Pedersen, Anne Øberg Lauritsen, Kirsten Møller, Peter Garred Amyotrophic lateral sclerosis (ALS) is a devastating, neurodegenerative motor neuron disease. The aetiology of ALS remains an enigma which hinders the design of an effective treatment to prevent, postpone, or reverse the pathophysiological changes occurring during the aggressive progression of this disease. During the last decade, basic research within the innate immune sy...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Ebel et al. evaluated the association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS) [1]. Sociodemographic factors and physical activities were also considered in the analysis. The authors cited a paper, presenting the hypothesis that there was a pathophysiological link between ADHD and ALS [2], however ALS patients reported a lower prevalence of childhood ADHD and there was no evidence that ADHD had been more common in ALS patients. I have 2 concerns about this study.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Xueping Chen, Qian-Qian Wei, Yongping Chen, Bei Cao, RuWei Ou, Yanbing Hou, Xiaoqin Yuan, Lingyu Zhang, Hui Liu, Huifang Shang
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: Available online 18 June 2018 Source:Molecular and Cellular Neuroscience Author(s): Rachit Bakshi, Yuehang Xu, Kaly A. Mueller, Xiqun Chen, Eric Granucci, Sabrina Paganoni, Ghazaleh Sadri-Vakili, Michael A. Schwarzschild Dominant mutations in an antioxidant enzyme superoxide dismutase-1 (SOD1) cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease characterized by loss of motor neurons. Oxidative stress has also been linked to many of the neurodegenerative diseases and is likely a central mechanism of motor neuron death in ALS. Astrocytes derived from mutant SOD1 G93A mouse m...
Source: Molecular and Cellular Neuroscience - Category: Neuroscience Source Type: research
Abstract Cannabinoid receptor CB2 (CB2R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurological diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. The advent of positron emission tomography (PET) using CB2R radiotracers has enabled the visualization of CB2R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful. Several novel CB2R radiotracers have been developed and evaluated to quantify microglial activation. ...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
The S-oxidation of S-carboxymethyl-L-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson ’s disease and Amyotrophic lateral sclerosis. In this investigation, the original observations have been confirmed with the incidence of the poor metaboliser phenotype (no urinary recovery of S-oxide metabolites) being found to be 3.9% within healthy control population. However, 38.3% of the Parki nson’s disease subjects and 39.0% of the Amyotrophic lateral sclerosis group were phenotyped as poor metabolisers.
Source: Medical Hypotheses - Category: Biomedical Science Authors: Source Type: research
Publication date: Available online 19 June 2018 Source:The Lancet Neurology Author(s): Albert C Ludolph, Joachim Schuster, Johannes Dorst, Luc Dupuis, Jens Dreyhaupt, Jochen H Weishaupt, Jan Kassubek, Ulrike Weiland, Susanne Petri, Thomas Meyer, Julian Grosskreutz, Berthold Schrank, Matthias Boentert, Alexander Emmer, Andreas Hermann, Daniel Zeller, Johannes Prudlo, Andrea S Winkler, Torsten Grehl, Michael T Heneka, Siw Wollebæk Johannesen, Bettina Göricke Background Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD...
Source: The Lancet Neurology - Category: Neurology Source Type: research
More News: ALS | Biotechnology | Pharmaceuticals